Stocks
Merck & Co., Inc.MRK
NYSEHealthcarePharmaceuticals$115.62-0.25%
A global pharmaceutical company focused on prescription medicines, vaccines, and biologic therapies, Merck generates a significant share of revenue from its oncology franchise, led by blockbuster immunotherapy Keytruda. The company also maintains a sizable vaccines business and an expanding pipeline in oncology, infectious diseases, and cardiometabolic conditions. Investors monitor patent expiration timelines, clinical trial outcomes, and capital allocation as key drivers of long-term earnings growth.
Market Cap: $285.9B52W Range: $73.31 – $125.14
Congressional Interest in Merck & Co., Inc. (MRK)
16 members of Congress have disclosed 50 trades in Merck & Co., Inc. (MRK), a Healthcare company. The buy/sell breakdown shows 23 purchases versus 27 sales, indicating net selling pressure from lawmakers. All data is sourced from STOCK Act periodic transaction reports filed with Congress.
Total Disclosures
50
Unique Politicians
16
Buys
23
Sells
27
Who in Congress Is Trading MRK?
| Date | Politician | Type | Amount |
|---|---|---|---|
| 2025-02-25 | Rob Bresnahan | sell | $15K – $50K |
| 2025-02-24 | Jefferson Shreve | buy | $15K – $50K |